[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Certara's First Quarter Report Arrives With New Leadership and Reset Growth Targets

Certara Inc (CERT) reports first quarter 2026 earnings before market open on May 11, 2026, with analysts expecting $0.07 per share—a sharp 30% decline from the $0.10 reported in the same quarter last year. The biosimulation software and services provider faces a critical test as investors weigh whether recent execution challenges and external headwinds will persist or if the company's strategic reset under new CEO Jon Resnick can stabilize growth. With the stock trading well below its 100-day and 200-day moving averages and technical signals flashing caution, this report will determine whether CERT can regain momentum or faces further downside.

Fundamentals

See More
  • Market Capitalization, $K 967,481
  • Shares Outstanding, K 153,325
  • Annual Sales, $ 418,840 K
  • Annual Income, $ -1,600 K
  • EBIT $ 78 M
  • EBITDA $ 153 M
  • 60-Month Beta 1.53
  • Price/Sales 2.31
  • Price/Cash Flow 8.34
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 204.94% (-34.26%)
  • Historical Volatility 45.65%
  • IV Percentile 66%
  • IV Rank 29.59%
  • IV High 555.01% on 02/12/26
  • IV Low 57.81% on 01/16/26
  • Expected Move (DTE 5) 0.20 (3.10%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 42
  • Volume Avg (30-Day) 348
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 6,650
  • Open Int (30-Day) 6,904
  • Expected Range 6.11 to 6.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.07
  • Number of Estimates 3
  • High Estimate $0.08
  • Low Estimate $0.06
  • Prior Year $0.10
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.19 +21.58%
on 04/09/26
6.48 -2.62%
on 04/22/26
+0.88 (+16.21%)
since 04/08/26
3-Month
5.19 +21.58%
on 04/09/26
7.52 -16.09%
on 03/05/26
-0.92 (-12.72%)
since 02/06/26
52-Week
5.19 +21.58%
on 04/09/26
13.88 -54.54%
on 10/03/25
-5.56 (-46.84%)
since 05/08/25

Most Recent Stories

More News
Certara's First Quarter Report Arrives With New Leadership and Reset Growth Targets

Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...

CERT : 6.31 (unch)
Certara's First Quarter Report Arrives With New Leadership and Reset Growth Targets

Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...

CERT : 6.31 (unch)
Certara's First Quarter Report Arrives With New Leadership and Reset Growth Targets

Barchart Research What to Expect from CERT Earnings CERT Generated May 8, 2026 Current Price $6.29 EPS Estimate $$0.07 Consensus Rating Moderate Buy Average Move 9.84% Certara's First Quarter Report Arrives...

CERT : 6.31 (unch)
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Altasciences , a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed...

CERT : 6.31 (unch)
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence  Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE...

CERT : 6.31 (unch)
Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first...

CERT : 6.31 (unch)
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp ® Simulator enabled physiologically-based...

CERT : 6.31 (unch)
Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following...

CERT : 6.31 (unch)
Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance

FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of...

CERT : 6.31 (unch)
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025

RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth...

CERT : 6.31 (unch)

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 6.78
2nd Resistance Point 6.62
1st Resistance Point 6.46
Last Price 6.31
1st Support Level 6.14
2nd Support Level 5.98
3rd Support Level 5.83

See More

52-Week High 13.88
Fibonacci 61.8% 10.56
Fibonacci 50% 9.53
Fibonacci 38.2% 8.51
Last Price 6.31
52-Week Low 5.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.